Roivant Sciences Ltd (FRA:87S)
€ 11.525 0.15 (1.32%) Market Cap: 8.62 Bil Enterprise Value: 3.56 Bil PE Ratio: 2.21 PB Ratio: 1.78 GF Score: 60/100

Roivant Sciences Ltd at Cantor Fitzgerald Global Healthcare Conference Transcript

Sep 27, 2023 / 03:30PM GMT
Release Date Price: €12.3 (+8.85%)
Louise Alesandra Chen
Cantor Fitzgerald & Co., Research Division - MD & Senior Research Analyst

Good day, I'm Louise Chen, the large-cap pharma, Biopharma and Biotech Analyst here at Cantor. We're very pleased to have with us today, Matthew Gline, who is the CEO of Roivant Pharmaceuticals.

So to start, Matthew for people that are newer to the story, if you could give a brief overview of the company and what your strategic vision is for the next 3 to 5 years for Roivant.

Matthew Gline
Roivant Sciences Ltd. - CEO & Director

Sure. And first of all, just thank so much for having us. It's great to be here. It's been a good conference already. We're looking forward to it. So really appreciate your hosting. Yes, who are we? So we are a $9.5-ish billion market cap biotech company. We are trying to do what everybody is trying to do, which is to develop medicines that matter. We do that in some unusual ways. We're not set up as a monolithic kind of a command and control organization. We're up as a family of independent biotech companies that we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot